LGT Group Foundation Takes Position in Insulet Co. (NASDAQ:PODD)

LGT Group Foundation purchased a new stake in shares of Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,083 shares of the medical instruments supplier’s stock, valued at approximately $238,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wolff Wiese Magana LLC raised its holdings in shares of Insulet by 2,680.0% during the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 134 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Insulet by 251.0% during the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 123 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Insulet by 104.5% during the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 92 shares in the last quarter. Lindbrook Capital LLC raised its holdings in shares of Insulet by 64.1% during the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after purchasing an additional 75 shares in the last quarter. Finally, BluePath Capital Management LLC bought a new position in shares of Insulet during the 3rd quarter valued at $31,000.

Analyst Ratings Changes

Several research analysts recently commented on PODD shares. Piper Sandler dropped their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. JPMorgan Chase & Co. lifted their target price on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Stifel Nicolaus lifted their target price on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a report on Monday, February 5th. Finally, Barclays dropped their target price on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a report on Monday, February 26th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $243.21.

Insulet Stock Performance

NASDAQ PODD opened at $174.43 on Friday. The firm has a market capitalization of $12.21 billion, a price-to-earnings ratio of 59.94, a P/E/G ratio of 3.12 and a beta of 1.00. The company’s fifty day moving average is $169.57 and its two-hundred day moving average is $180.68. Insulet Co. has a 52-week low of $125.82 and a 52-week high of $335.91. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.73. The firm had revenue of $509.80 million during the quarter, compared to analysts’ expectations of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.55 earnings per share. Equities research analysts forecast that Insulet Co. will post 3.08 EPS for the current year.

Insiders Place Their Bets

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the transaction, the director now owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.47% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.